Philadelphia, PA, Monday, June 25, 2001: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today it will co-sponsor the Global HEALTH Organization (GHO) Inaugural Dinner at the United Nations in New York on Tuesday, June 26. The GHO Inaugural Dinner will raise money to provide medical aid for the treatment of HIV and AIDS in Africa, and worldwide.
Dr. William Carter, Hemispherx chairman, president, and chief executive officer, said, “We are proud to be a part of the Global AIDS Fundraiser to address the critical needs of people with HIV/AIDS,” said. “It is our belief that our NA platform technology for the potential treatment of HIV, via novel immune mechanisms, represents a new therapeutic frontier for developing nations. The company’s lead investigational NA product, Ampligen®, is currently in Phase IIb clinical trials, and may also help address this epidemic in southern Africa and on a worldwide basis.”
According to Dr. Gary Blick, GHO chairman, “The continent of Africa has 25 million people infected with HIV after 17 million have already died. That translates into a major catastrophe of epidemic proportions due to the silence in the western world.”
GHO is the private, non-profit humanitarian aid organization that provides healthcare, establishes medical programs, and offers efficient and effective solutions to world health problems for all individuals in need throughout the world. The GHO plans to continue AIDS education and treatment programs by opening new clinics in Capetown, South Africa, and Brooklyn, NY.
About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Philadelphia, PA, has devoted nearly three decades to exploring, understanding, and mastering the mechanism of ribonucleic acid (RNA) drug technology. The Company's longevity as a biomedical research and drug development institution, coupled with its record of enduring scientific achievement, is evidence of long-term commitment to these promising new classes of drugs for the chronically ill and to bring new therapeutic choices to the global health care community. For more information, please visit the company’s website at www.hemispherx.net.
Contact(s):
William A. Carter, M.D.
(215) 988-0080
CEO & Chairman
or
Investor Relations
Dianne Will, (518) 398-6222
Fax: (518) 398-6223
www.hemispherx.net
KCSA Bob Giordano / Michael Cimini
CONTACTS:
(212) 896-1289
(212) 896-1233
rgiordano@kcsa.com / mcimini@kcsa.com
Information contained in this news release other than historical information, should all be considered forward-looking and are subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
This release is available on the KCSA Public Relations Worldwide Web site at www.kcsa.com.
|
